Argen X SE
Research Argen X SE (ARGX) on Bullrun: market cap USD 63.40B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerARGX
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 63.40B
- Financial periodQ2 2026
- RevenueUSD 1.52B
- Net incomeUSD 472.00M
- Gross margin90.4%
Valuation Snapshot
latest market cap is USD 63.40B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.15B | USD 1.29B | n/a | 89.1% | 46.98 | USD 3.49B | USD 47.16M | USD 7.32B |
| FY2024 | USD 2.19B | USD 833.04M | n/a | 89.6% | 9.63 | USD 1.50B | USD 39.05M | USD 5.50B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 63.40B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 52.04B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 37.37B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 22.48B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 20.96B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 18.09B | n/a | n/a | n/a |
About Argen X SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Argen X SE's market cap?
Argen X SE's market capitalization is USD 63.40B.
What does Argen X SE do?
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).